Lung Cancer (Diagnosis)NCT07288710
A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy
An observational study of Lung Cancer (Diagnosis) and Lobectomy, run by The First Affiliated Hospital of Guangzhou Medical University at 1 site in China.
Trial summary
The trial was designed as a single-center, non-interventional, prospective observational study to explore the role of a multimodal digital device in analyzing subjective and objective recovery in lung cancer patients undergoing sublobar resection versus lobectomy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer (Diagnosis), Lobectomy, Sublobar Resection
- How many people
- 316 participants
- Where
- 1 siteChina
- Study dates
- 9 Mar 2023to 20 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients with histopathologically confirmed lung cancer were consecutively recruited
Who may be able to join
- adult patients (age ≥ 18 years)
- American Society of Anesthesiologists (ASA) grade of III or below
- scheduled for VATS from March to December 2023
Who cannot join
- age <18 years
- inability or poor compliance to use wearable devices
- lack of smartphone
- incomplete digital device data during hospitalization
- patients with lymph node or distant metastasis
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong
About this study
Official title: A Prospective Observational Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy
The trial was designed as a single-center, non-interventional, prospective observational study to explore the role of a multimodal digital device in analyzing subjective and objective recovery in lung cancer patients undergoing sublobar resection versus lobectomy.
- Conditions
- Lung Cancer (Diagnosis), Lobectomy, Sublobar Resection
- Medical subject headings
- Lung Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Sublobar Resection Group | Patients in this group underwent sublobar resection (including segmentectomy or wedge resection). The decision for patients to receive this surgical procedure was similarly based on their routine clinical assessment, disease characteristics, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients, comparing them to the lobectomy group. | |
| Lobectomy Group | Patients in this group underwent standard lobectomy. The decision for patients to receive this surgical procedure was based on their routine clinical assessment, diagnosis, disease staging, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Electronic patient-reported outcomes
The electronic patient-reported outcomes questionnaire includes pain, cough, shortness of breath, restless sleep, fatigue, drowsiness, walking difficulties, activity limitation, and distress(0 = no symptom, 10 = most severe).
Measured: From 1 day prior to surgery through hospital discharge (assessed up to 15 days).
Secondary outcomes (3)
Length of Hospital Stay
Total number of days spent in the hospital from admission to discharge.
Measured: From the day of surgery until the day of discharge, assessed up to 15 days.
Surgical Time
Duration of the surgery measured in hours.
Measured: During the surgical procedure (from anesthesia induction until skin closure).
Number of Lymph Nodes Dissected
The total count of lymph nodes harvested during the surgical procedure.
Measured: During the surgical procedure (from anesthesia induction until skin closure).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2025
- Study start9 Mar 2023
- Primary completion10 Dec 2025
- Study completion20 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 316 participants (actual)
Sponsor and investigators
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07288710
- Sponsor's protocol ID
- GMU-LC-202511
- Status last verified
- Jun 2026
- First submitted
- 19 Nov 2025
- Last updated
- 16 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Observational Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy
- ClinicalTrials.gov ID
- NCT07288710
- Acronym / sponsor ID
- GMU-LC-202511
- Conditions
- Lung Cancer (Diagnosis), Lobectomy, Sublobar Resection
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 316 participants (actual)
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical UniversityUniversity, hospital or other
- Study start
- 9 Mar 2023 (actual)
- Primary completion
- 10 Dec 2025 (actual)
- Study completion
- 20 Apr 2026 (actual)
- First posted
- 17 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The trial was designed as a single-center, non-interventional, prospective observational study to explore the role of a multimodal digital device in analyzing subjective and objective recovery in lung cancer patients undergoing sublobar resection versus lobectomy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sublobar Resection Group | – | –Patients in this group underwent sublobar resection (including segmentectomy or wedge resection). The decision for patients to receive this surgical procedure was similarly based on their routine clinical assessment, disease characteristics, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients, comparing them to the lobectomy group. |
| Lobectomy Group | – | –Patients in this group underwent standard lobectomy. The decision for patients to receive this surgical procedure was based on their routine clinical assessment, diagnosis, disease staging, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients with histopathologically confirmed lung cancer were consecutively recruited
Key inclusion criteria (3 listed)
- adult patients (age ≥ 18 years)
- American Society of Anesthesiologists (ASA) grade of III or below
- scheduled for VATS from March to December 2023
Key exclusion criteria (5 listed)
- age <18 years
- inability or poor compliance to use wearable devices
- lack of smartphone
- incomplete digital device data during hospitalization
- patients with lymph node or distant metastasis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Electronic patient-reported outcomes
Time frame: From 1 day prior to surgery through hospital discharge (assessed up to 15 days).
The electronic patient-reported outcomes questionnaire includes pain, cough, shortness of breath, restless sleep, fatigue, drowsiness, walking difficulties, activity limitation, and distress(0 = no symptom, 10 = most severe).
3 secondary outcomes
Length of Hospital Stay
Time frame: From the day of surgery until the day of discharge, assessed up to 15 days.
Surgical Time
Time frame: During the surgical procedure (from anesthesia induction until skin closure).
Number of Lymph Nodes Dissected
Time frame: During the surgical procedure (from anesthesia induction until skin closure).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer (Diagnosis)
Active, not recruitingPhase 2
Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy
Radiation of Neurocranial Region
RecruitingPhase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung Cancer, NSCLC
RecruitingPhase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
RecruitingPhase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small-Cell Lung
Not yet recruitingPhase 1/2
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer (Diagnosis) and Lobectomy, run by The First Affiliated Hospital of Guangzhou Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Electronic patient-reported outcomes (time frame: From 1 day prior to surgery through hospital discharge (assessed up to 15 days).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026.